Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

被引：0
|
作者：
Anna Maria Di Giacomo
Luana Calabrò
Riccardo Danielli
Ester Fonsatti
Erica Bertocci
Isabella Pesce
Carolina Fazio
Ornella Cutaia
Diana Giannarelli
Clelia Miracco
Maurizio Biagioli
Maresa Altomonte
Michele Maio
机构：
[1] University Hospital of Siena,Division of Medical Oncology and Immunotherapy, Department of Oncology, Istituto Toscano Tumori
[2] Regina Elena National Cancer Institute,Statistical Unit
[3] University Hospital of Siena,Department of Pathology
[4] University Hospital of Siena,Department of Dermatology
来源：
Cancer Immunology, Immunotherapy | 2013年 / 62卷
关键词：
Biomarker; Expanded access programme; Ipilimumab; Long-term survival; Metastatic melanoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1021 / 1028
页数：7
相关论文
共 50 条
  • [21] Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma
    Kitano, Shigehisa
    Postow, Michael Andrew
    Cortez, Czrina
    Rasalan, Teresa
    Gallardo, Humilidad F.
    Panageas, Katherine
    Yuan, Jianda
    Wolchok, Jedd D.
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Spanish Melanoma Multidisciplinary Group (gem): Long term survivors (LTS) treated with ipilimumab (IPI) in the expanded access programme (EAP)
    Berrocal, A.
    Valdivia, J.
    Martin Algarra, S.
    Espinosa, E.
    Curiel, T.
    Puertolas, T.
    Mut, P.
    Ochoa, M.
    Ballesteros, A.
    Marquez, I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S870 - S870
  • [23] Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine
    Hersh, E.
    Weber, J.
    Powderly, J.
    Pavlik, A.
    Nichol, G.
    Yellin, M.
    Cranmer, L.
    Urba, W.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide
    Kim, Christina
    Lee, Christopher W.
    Kovacic, Laurel
    Shah, Amil
    Klasa, Richard
    Savage, Kerry J.
    ONCOLOGIST, 2010, 15 (07): : 765 - 771
  • [25] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
    Ascierto, Paolo Antonio
    Del Vecchio, Michele
    Mackiewicz, Andrzej
    Robert, Caroline
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Svane, Inge Marie
    McNeil, Catriona
    Rutkowski, Piotr
    Loquai, Carmen
    Mortier, Laurent
    Hamid, Omid
    Bastholt, Lars
    Dreno, Brigitte
    Schadendorf, Dirk
    Garbe, Claus
    Nyakas, Marta
    Grob, Jean-Jacques
    Thomas, Luc
    Liszkay, Gabriella
    Smylie, Michael
    Hoeller, Christoph
    Ferraresi, Virginia
    Grange, Florent
    Gutzmer, Ralf
    Pikiel, Joanna
    Hosein, Fareeda
    Simsek, Burcin
    Maio, Michele
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [26] Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
    Ascierto, Paolo A.
    Del Vecchio, Michele
    Mackiewicz, Andrzej
    Robert, Caroline
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Svane, Inge Marie
    McNeil, Catriona
    Rutkowski, Piotr
    Loquai, Carmen
    Mortier, Laurent
    Hamid, Omid
    Bastholt, Lars
    Dreno, Brigitte
    Schadendorf, Dirk
    Garbe, Claus
    Nyakas, Marta
    Grob, Jean-Jacques
    Thomas, Luc
    Liszkay, Gabriella
    Smylie, Michael
    Burcin, Simsek
    Hosein, Fareeda
    Maio, Michele
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
  • [27] Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma
    Bedikian, Agop Y.
    Johnson, Marcella M.
    Warneke, Carla L.
    Papadopoulos, Nicholas E.
    Kim, Kevin
    Hwu, Wen-Jen
    Mclntyre, Susan
    Hwu, Patrick
    CANCER INVESTIGATION, 2008, 26 (06) : 624 - 633
  • [28] Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting
    B. M. Lang
    A. Peveling-Oberhag
    D. Faidt
    A. M. Hötker
    V. Weyer-Elberich
    S. Grabbe
    C. Loquai
    Medical Oncology, 2018, 35
  • [29] PROJECTING LONG TERM OVERALL SURVIVAL BENEFIT IN METASTATIC MELANOMA PATIENTS TREATED WITH IPILIMUMAB USING EXTRAPOLATION METHODS
    Kim, Hansoo
    Cook, Greg
    McCloud, Philip
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 313 - 313
  • [30] Serum protein predictors of long term survival from combined ipilimumab and nivolumab therapy in metastatic melanoma patients
    Homicsko, Krisztian
    Cuendet, Michel A.
    Michielin, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345